Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated transcriptomic analysis reveals KRAS-associated gene activation and epigenetic regulation in mutant IDH1 glioma.

Genes & genomics - 1 Jul 2026

Jeon Jinha, Park Jiyoon, Gim Sujeong, Chung Chan

Abstract excerpt

BACKGROUND: Mutations in isocitrate dehydrogenase 1 (IDH1) are hallmark features of diffuse gliomas and drive extensive metabolic and epigenetic reprogramming through accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). However, the downstream transcriptional programs and chromatin-based mechanisms linking mutant IDH1 to oncogenic signaling remain incompletely understood. OBJECTIVE: This study aimed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Epigenesis, Genetic
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Histone-Lysine N-Methyltransferase

Share to Isocitrate Dehydrogenase

Share to Proto-Oncogene Proteins p21(ras)

Share to Transcriptome

Source

Identifiers

PMID: 42159965
DOI: 10.1007/s13258-026-01775-7

Genes

IDH1
KRAS
SETD2
SMYD5

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated transcriptomic analysis reveals KRAS-associated gene activation and epigenetic regulation in mutant IDH1 glioma.PMID 42159965Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in <i>IDH1</i> -mutant gliomaSemantic proximity Read ↗

Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.Semantic proximity Read ↗

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling.Semantic proximity Read ↗

Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.Semantic proximity Read ↗

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets.Semantic proximity Read ↗

Mutant IDH1 Promotes Glioma Formation In VivoSemantic proximity Read ↗

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma CellsSemantic proximity Read ↗

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.Semantic proximity Read ↗

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.Semantic proximity Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.